Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Stock Dives 13 Percent on Disappointing Q3 Results

NEW YORK, Nov. 2 (GenomeWeb News) - Shares in Third Wave were down 13.2 percent, or $.47, at $3.08 in mid-afternoon trading after the company announced this morning that  third-quarter revenue fell by half and net losses grew more than 300 fold.

 

As GenomeWeb News reported earlier today, Third Wave's blamed its revenue decline on a "reduction in non-recurring research revenue from Japan." It also said that growth related to molecular diagnostics has been "flat."

 

Separately today, research firm Caris & Company downgraded the stock to "Below Average" from "Average."

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.